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Abstract: The increasing pressure on health resources has led to the emergence of risk 
assessment as an essential tool in the management of cardiovascular disease (CVD). Concern 
exists regarding the validity of their generalization to all populations. Existing risk scoring mod-
els do not incorporate emerging ‘novel’ risk factors. In this context, the aim of the study was 
to examine the relevance of British, European, and Framingham predictive CVD risk scores to 
the asymptomatic high risk Indian population. Blood samples drawn from the participants were 
analyzed for various ‘traditional’ and ‘novel’ biomarkers, and their CVD risk factor proﬁ  ling was 
also done. The Framingham model deﬁ  ned only 5% of the study cohort to be at high risk, which 
appears to be an underestimation of CVD risk in this genetically predisposed population. These 
subjects at high risk had signiﬁ  cantly elevated levels of lipid, pro-inﬂ  ammatory, pro-thrombotic, 
and serological markers. It is more relevant to develop risk predictive scores for application 
to the Indian population. This study substantiates the argument that alternative approaches to 
risk stratiﬁ  cation are required in order to make them more adaptable and applicable to different 
populations with varying risk factor and disease patterns.
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Introduction
Atherosclerotic cardiovascular disease (CVD) resulted in 17.5 million deaths in 2005, 
representing 30% of all the global deaths (WHO 2005). Despite major advances in 
treatment of ischemic heart disease (IHD) patients, a large number of victims of the 
disease who are apparently healthy die suddenly without prior symptoms. Available 
screening and diagnostic methods are insufﬁ  cient to identify the victims before the 
event occurs. The ﬁ  rst detectable clinical manifestation of atherosclerosis is often 
a clinical event: a stroke or myocardial infarction (MI). Atherosclerosis, being a 
chronic process, undergoes a series of changes in the arterial walls before the clini-
cal endpoints set in. This includes endothelial damage, lipid inﬁ  ltration, followed by 
intimal thickening, platelet adherence, smooth muscle cell proliferation and plaque 
formation. Rupture of the plaque is the ﬁ  nal event that results in a clinical endpoint 
(Ross 1993, 1999).
The World Health Organization has projected that CVD will become the greatest 
cause of morbidity and mortality in the world by the year 2015 (WHO 2000); and it 
is expected that Indians would be the most affected amongst all ethnic populations 
(Murray and Lopez 1996). Primary prevention in terms of risk stratiﬁ  cation is pivotal 
in order to accurately determine and intervene early in the natural history of disease. 
One goal in risk factor research is to move ever closer to the proximal direct causes 
of disease (Stampfer et al 2004). A complementary goal is to improve prediction to 
identify individuals who are more likely to develop CVD and who therefore should be Vascular Health and Risk Management 2008:4(1) 200
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receiving more intensive interventions where possible. The 
focus is on maximizing the beneﬁ  t/cost ratio of treatments 
(Stampfer et al 2004). To this effect, the risk assessment 
deﬁ  ned by the Framingham Study researchers was a great 
leap forward (Wilson et al 1998). This lead to the develop-
ment of multiple predictive CVD risk score calculators, such 
as the Munster Heart Study (PROCAM) Risk Score (Green-
land et al 2001), Shefﬁ  eld Coronary Risk Tables (Ramsay 
et al 1996), National Heart Foundation of New Zealand 
Guidelines (Greenland et al 2001), Dundee Coronary Risk 
Disc (Greenland et al 2001), and the SCORE project (Conroy 
et al 2003) among others. While there is some evidence that 
risk estimates based on Framingham data generalize well to 
other populations in the US (D’Agostino et al 2001) and in 
Europe (Haq et al 2001), many studies in the US and Europe 
have shown that Framingham risk factors overestimate the 
risk of CAD in Hispanics and northern Europeans, some 
Asians (Japanese, Chinese) (Cappuccio et al 2002; Thomsen 
et al 2002; Hense et al 2003). A recent study on the Chinese 
cohort found the Framingham model overestimated the CAD 
risk (Liu et al 2004; Asia Paciﬁ  c Cohort Studies Collabora-
tion 2007). Similarly, the application of the Framingham 
risk score on the Danish population lead to an overestimation 
of coronary risk (Thomsen et al 2002; de Visser et al 2003). 
There are also many studies which show underestimation 
of CAD risk by the Framingham model (Brindle et al 2005; 
Reissigova and Zvarova 2007). Thus, it is evident that preva-
lence of risk varies between ethnic groups and thus there is 
a need for population speciﬁ  c risk estimations.
Although risk-scoring systems that evaluate ‘traditional’ 
risk factors such as lipids, hypertension, diabetes, and 
smoking greatly improve risk prediction, multiple studies 
demonstrate that 20% to 25% of all future events occur in 
individuals with only 1 of these factors (Ridker et al 2004). 
Moreover, the prevalence of traditional risk factors is almost 
as high in those without disease as in affected individuals 
(Ridker et al 2004). There are many emerging risk factors 
that were not considered in these risk computations. With 
evolving understanding of the pathophysiology of CAD, it 
is more than likely that other risk factors may greatly inﬂ  u-
ence an individual’s overall risk burden (Heman et al 2007). 
Indeed, a series of candidate biomarkers reﬂ  ecting inﬂ  amma-
tion, hemostasis, thrombosis, and oxidative stress have been 
evaluated as potential clinical tools in an effort to improve 
risk prediction (Ridker et al 2004).
India is now in the middle of a CAD epidemic. The CAD 
rates among Asian Indians worldwide are 50% to 400% 
higher than people of other ethnic origin and at least 4 times 
that of Caucasians (Enas and Senthilkumar 2001). It appears 
that at a given level of any single or combination of conven-
tional risk factors, the CAD rates among Asian Indians are 
at least double that of Caucasians. Asian Indians, compared 
with other subpopulations, are at more risk for developing 
CAD and Diabetes at a younger age (approximately 10 years) 
(see www.aapio.org; McKeigue et al 1989, 1991). Obser-
vational studies from Singapore, Malaysia, UK, and US 
have shown that differences in age-standardized mortality 
in Asian Indians is highest in patients under 40 yrs of age 
compared with other populations (Lee et al 2001). The low 
prevalence of standard risk factors in Indians seems to be 
negated by a higher prevalence of several emerging risk 
factors (see www.aapio.org; Anand et al 2000).Therefore, a 
more aggressive approach to prevention and treatment of both 
conventional and emerging risk factors is warranted in the 
Asian Indians (see www.aapio.org; Enas and Senthilkumar 
2001). No predictive CVD risk score is currently available 
for the Indians considered to be a high-risk population. In 
this context the aim of this study was: 1. To apply three 
different ten year predictive CVD risk scoring systems to 
a high-risk cohort of Asian Indian families with premature 
onset of coronary artery disease and to deﬁ  ne their quantita-
tive risk; 2. To compare CVD risk prevalence between the 
different systems; 3. To assess differences in risk factors if 
any, between subjects that were categorized as high risk and 
low risk for CVD, and lastly; 4. To evaluate the association 
of ‘novel’ plasma biomarkers to the calculated risk scores.
Materials and methods
The current study was conducted on a cohort enrolled into 
the Indian Atherosclerosis Research Study (IARS), by the 
Thrombosis Research Institute-India (TRI-India). The IARS 
is an ongoing family based genetic epidemiological study, 
with an aim to investigate the genetic factors associated with 
CAD, as also their interaction with traditional risk factors in 
a cohort of Asian Indian population in their home country. 
The families in the IARS were enrolled from two cities   
– Bangalore in South India and Mumbai in Western India. 
The recruitment for this particular study was from March 
2003–July 2005. The subjects were ascertained through a 
proband (males  60 years; females  65 years at onset of 
CAD) admitted to Narayana Hrudayalaya, a multi-specialty 
hospital and other tertiary care hospitals in Bangalore and 
to the Asian Heart Institute in Mumbai for undergoing treat-
ment for CAD and its complications. Only probands with a 
positive family history of coronary disease or CVD were 
enrolled into the study. A detailed pedigree of the families Vascular Health and Risk Management 2008:4(1) 201
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of each proband was drawn and their family members (both 
CVD affected and unaffected) were subsequently enrolled 
into the study, provided they were 18 years or above in age 
at the time of recruitment. None of the probands or family 
members had concomitant or past major illness such as 
cancer, cardiomyopathy, rheumatic heart disease, liver or 
renal disease or concomitant infection. In total, ﬁ  ve hundred 
and thirty families comprising of 2316 individuals, 1355 
males and 961 females were enrolled, with a mean of 4.37 
individuals per family.
Case record form
A detailed case record form containing information on demo-
graphics, socio economic status, medical history of diabetes, 
hypertension, and CVD was recorded for all the subjects. A 
general physical examination along with anthropometrical 
measures and vital parameters was also conducted for all 
participants in this study. Relevant information was obtained 
by personal interviews and through medical records avail-
able with the subjects and/or from the hospital records. The 
prevalence of diabetes, hypertension, and CVD was ascer-
tained based on self-report of physician’s diagnosis and/or 
use of prescription medications along with medical records 
of therapeutics. All participants gave their written informed 
consent to participate in the study that was approved by the 
local Ethics Committee.
Laboratory assays
Venous blood was collected in evacuated tubes after an 
overnight fast of 12 to 14 hours (Vacuette®, Greiner Bio-One 
GmbH, Vienna, Austria). Serum, EDTA and Citrate plasma 
samples were separated by centrifugation within 2 hours 
of sampling and aliquots were preserved at −80 °C until 
analysis. Fasting venous blood sugar was assayed using a 
Glucometer (Bayer Diagnostics) for all participants. Serum 
TG was estimated using reagents, standards and controls 
from Randox Laboratories Ltd., Antrim, UK. Estimation 
of high density lipoprotein-cholesterol (HDL-C) levels was 
carried out by the Phosphotungstate method using precipitat-
ing agents and buffer from Bayer Diagnostics, control from 
Randox Labs, and standards from Dade-Behring Limited, 
UK. The Standards, reagents and controls for measuring total 
cholesterol (TC) and Lp (a) were procured from Randox Lab-
oratories. ApoA1, ApoB100 (Orion diagnostics), Fibrinogen, 
FVII (Instrumentation Laboratories), and high sensitivity 
C-reactive protein (hsCRP) (Roche Diagnostics). Levels 
of oxidized-low density lipoprotein (LDL) (Mercodia), 
PAI-1 (Diagnostoica Stago), CRP (IBL), interleukin 
(IL)-6, sICAM, P-selectin, adiponectin (R&D Systems), and 
Leptin (Bioline) were assayed by ELISA. The lipid assays 
were carried out on Cobas-Fara II Clinical Chemistry Auto 
analyzer (F. Hoffman La Roche Ltd., Basel, Switzerland). 
LDL was calculated using Friedwald’s formula in all samples 
with a TG  400 mg/dl. The coagulation parameters were 
analyzed on ACL 300 (IL systems, Milano, Italy). The 
hsCRP was assayed by the Latex method on the Cobas-Fara 
II analyser. The serological assays were ELISA-based. The 
CMV kits were procured from Adaltis (Italy), C.pneumoniae 
and HSV1 kits from Calbiotech (USA) and Helicobacter 
pylori kits from Medical Biological Services (Italy). ELISA-
based HSP 60 and 70 were assayed with kits from Stressgen 
Biotechnologies (UK). Antibodies to HSP 65 were measured 
by in house ELISA.
CVD risk assessment
Risk score computations were based on estimates for the 
occurrence of fatal and non-fatal CVD within 10 years for 
all systems. Subjects with diagnosed CHD have a 20% 
10-year risk for developing future cardiac events includ-
ing acute myocardial infarction and cardiac death and thus 
are at high risk (Cobb et al 2003). Hence, risk scores were 
calculated for only the CVD-unaffected individuals in our 
cohort. Three different risk calculation tools along with their 
subsets, representing some of the most widely used tools and 
a spectrum of different formats (risk chart or electronic calcu-
lator), were selected for risk stratiﬁ  cation. The tools were the 
Framingham risk score (a paper chart) (Wilson et al 1998), 
the Joint British societies’ [BHS/BHA/BCS] recommenda-
tions (1998) on the prevention of CHD in clinical practice 
(a computer program) and the SCORE project estimations 
(chart) developed for risk scoring in the clinical management 
of CVD in European clinical practice (Conroy et al 2003). 
The risks obtained with each of the tools in accordance to 
published instructions on their use were divided into High 
risk ( 20%), Intermediate risk (10%– 20%), and Low risk 
( 10%). The nearest equivalent risk value was taken as the 
risk score from each scoring system. Listed below are the 
variables used for risk score computation by the different 
models used:
1.  Framingham Risk Score: Gender, age, total cholesterol 
(TC), HDL, systolic blood pressure (SBP), diastolic blood 
pressure (DBP), diabetes mellitus (DM), and smoking.
2.  The Joint British Cardiac Society (BCS)/British Hyper-
tension Society (BHS)/British Hyperlipidemia Associa-
tion (BHA) Risk Score: Gender, age, TC, HDL, SBP, 
DBP, DM, Smoking, ECG-LVH if available.Vascular Health and Risk Management 2008:4(1) 202
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3.  The European SCORE: Gender, age, TC, TC/HDL, SBP 
and smoking. The SCORE project has separate charts 
based on TC and TC/HDL, as also ones for high risk 
(Denmark, Finland, Norway) and low risk (Belgium, 
Italy, Spain) regions of Europe. We used all the above 
charts for computation.
Prevalence of metabolic syndrome amongst the cohort 
was assessed on the basis of the 2001 NCEP-ATP III 
(National Cholesterol Education Program – Adult Treatment 
Panel III) guidelines, wherein any three of the following traits 
in the same individual meet the criteria for the metabolic 
syndrome: abdominal obesity–waist circumference  102 cm 
(40 in) in men;  88 cm (35 in) in women; serum triglyc-
erides  150 mg/dL (1.7 mmol/L); HDL-C  40 mg/dl in 
men (1.03 mmol/L);  50 mg/dl (1.29 mmol/L) in women; 
blood pressure of  130/85 mm Hg; fasting blood glu-
cose  110 mg/dL (6.1 mmol/L).
Statistical analysis
The results are expressed as mean ± standard deviation for 
all continuous variables. Pearson’s partial correlation was 
carried out to investigate the inter-relationship amongst 
the various risk score calculating tools after adjustment 
for gender and age. Chi Square test with Yates correction 
was utilized to analyze the differences in the prevalence of 
high risk subjects as identiﬁ  ed using the various risk score 
calculators. While the mean levels for the various pheno-
types were calculated from the observed data, phenotypes 
that didn’t show normal distribution were log-transformed 
before performing statistical analyses. Independent samples 
Student T-test was employed to evaluate the difference in 
the means of various phenotypes between those at high risk 
and low risk for CVD as calculated by the Framingham risk 
score charts. For statistical comparison of the continuous 
variables, ANCOVA was used with adjustment for age, sex 
and BMI. A nominal two-sided p-value <0.05 was considered 
signiﬁ  cant. All of the above statistical tests were computed 
on SPSS v10 software.
Results
Five hundred and thirty one families comprising of 171 
nuclear and 337 extended families were recruited in the 
IARS. These families yielded 2313 individuals with 774 (632 
males and 142 females) CVD affected and 1542 (723 males 
and 819 females) unaffected people with regard to CVD. The 
mean age at onset of CVD of the affected people was 50.3 ± 
8.4 years for males and 53 ± 8.8 for females respectively, 
whilst the mean age at recruitment of unaffected subjects into 
IARS was 37.2 ± 14 years for males and 43.2 ± 13.7 years 
for females. 1285 of the unaffected subjects had a family 
history of premature onset CVD.
Risk scores were calculated for the 1542 unaffected 
individuals applying:
A. Framingham risk charts for males and females
B.  Low risk Framingham charts for the 2 sexes.
C.  The Joint British Societies’ SBP based CHD risk score.
D. The Joint British Societies’ DBP based CHD risk 
score.
E. The Joint British Societies’ SBP based Stroke risk 
score.
F.  The Joint British Societies’ DBP based Stroke risk 
score.
G. SCORE for high risk European countries based on TC.
H. SCORE for high risk European countries based on TC/
HDL.
I.  SCORE for low risk European countries based on TC.
J.  SCORE for low risk European countries based on TC/
HDL.
(All the risk scoring systems are denoted by the preceding 
alphabets mentioned above).
All the above Risk scores displayed a statistically sig-
niﬁ  cant correlation with one another (p = 0.000) due to near 
common variables used in their computation. Most of the 
subjects are deﬁ  ned to be at low risk for CHD in the next 
10 years as is evident from the Table 1 with the Framing-
ham (A), Joint British Societies’ CHD scores (C and D) and 
European SCORE for high risk regions (G and H). Only the 
Framingham (A) and the joint British Societies’ (C and D) 
CHD risk scoring systems deﬁ  ne 5.32%, 3.7%, and 4.41% 
of the cohort to be at high risk and 14.85%, 12.78%, and 
13.42% of people respectively, to be at intermediate risk for 
CVD in the forthcoming 10 years.
The Framingham score deﬁ  nes signiﬁ  cantly higher 
number of people at high risk when compared with all the 
other risk scoring tools used (Table 1B) and hence has been 
utilized for all further analysis. Of the high risk subjects 
deﬁ  ned by Framingham charts 61% are males as against 
39% females. The Joint British Societies’ systems also 
deﬁ  ne 82% and 75% males amongst the high risk subjects 
(Figure 2A). The gender distribution of people deﬁ  ned at 
intermediate risk by all the scoring systems was similar 
(Figure 2B). More women than men are found to be at low 
risk for CVD by all the risk scoring tools (Figure 2C). In 
males, age related increase of CHD risk is noted across all 
the above depicted systems (Figure 1A). A similar trend is 
witnessed amongst the females being signiﬁ  cantly lower Vascular Health and Risk Management 2008:4(1) 203
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Table 1A Risk score computations
Total unaffected  1542
Risk scoring  High risk     Intermediate risk   Low risk ( 10%)
tools ( 20%)   (10  %– 20%)
 N  %  N  %  N  %
A  82 5.32 229  14.85 1231 79.83
B 0  0  33  2.14  1057  68.55
C  57 3.7  197  12.78 1267 82.17
D  68 4.41 207  13.42 1246 80.8
E 0  0  10  0.65  1511  98
F 2  0.13  9  0.58  1510  97.92
G 1  0.06  12  0.78  1513  98.12
H 0  0  1  0.06  1525  98.9
I 4  0.26  17  1.1  1505  97.6
J 1  0.06  5  0.32  1520  98.57
than the male cohort in each of the corresponding age 
groups (Figure 1B).
We have used the term ‘traditional risk factors’ for all 
those factors that have been used to calculate the CVD risk 
scores. Table 2A does show signiﬁ  cantly higher levels of 
total cholesterol (TC) and TC/HDL in the high risk group as 
compared to the low risk group. HDL is signiﬁ  cantly lower 
in the high risk group of subjects. Similarly age, SBP, and 
DBP are much higher in the high risk group in relation to 
the low risk group (Table 2A). In view of the difference in 
the numbers between the two groups, all variables were log 
transformed and the p value calculated after adjusting for 
age, sex, and body mass index (BMI). Within the groups, 
there were more diabetics, smokers, and hypertensives in the 
high risk in comparison to the low risk group (Table 2A). 
Table. 3A illustrates the comparison of traditional risk fac-
tors between the high and intermediate risk groups calculated 
using the Framingham model. We found signiﬁ  cantly lower 
levels of HDL cholesterol, higher TC/HDL ratio, higher 
systolic blood pressure recordings and higher prevalence 
of diabetes, hypertension and smoking in the high risk 
group when compared to the intermediate risk group. All 
the traditional risk factors utilized in the computation of the 
risk scores were signiﬁ  cantly higher in the intermediate risk 
group in comparison to the low risk group, except for HDL 
cholesterol which was found to be signiﬁ  cantly lower in the 
intermediate risk group (Table 4A).
Novel biomarkers listed in Table 2B are those not used 
by the risk scoring tools. triglyceride (TG), LDL, Apolipo-
proteins A1 and B100, lipoprotein (a), CRP, hsCRP, oxidized 
LDL, P-selectin, Plasminogen activator inhibitor-1 (PAI-1) 
and Fibrinogen levels were found to be signiﬁ  cantly higher 
in the high risk group when compared with the low risk 
group. A similar trend was observed in the factor VII activity, 
leptin levels as also in the adiponectin levels (Table 2B). 
Signiﬁ  cantly higher levels of antibody titers against cyto-
megalovirus, Chlamydia pneumoniae and herpes simplex 
virus-1 were prevalent in the high risk in comparison with 
the low risk cohort. Heat shock protein 65 (HSP65) levels 
also showed a similar distribution. Table 2C summarizes 
our inference with regard to factors not used in calculation 
of the novel risk scores. BMI, waist circumference (WC), 
and waist-to-hip ratio (WHR) are signiﬁ  cantly higher in the 
high risk group. Large number of subjects in the low risk 
group also had family history of CVD. Good numbers of 
subjects at high risk were found to be exercising when com-
pared with the low risk group. Diet and alcohol intake did 
not show a signiﬁ  cant difference in distribution in between 
the two groups. A signiﬁ  cantly high number of people in the 
high-risk group had metabolic syndrome as deﬁ  ned by the 
NCEP–ATPIII 2001 criteria. Comparison of the novel plasma 
biomarkers between the high risk and the intermediate risk 
group revealed signiﬁ  cantly higher levels of triglycerides, 
LDL cholesterol, Apolipoprotein A1 and Apolipoprotein 
B100 in the high risk group. Inﬂ  ammatory markers like CRP, 
hsCRP, IL6, and prothrombotic biomarkers like ﬁ  brinogen, 
Table 1B Signiﬁ  cant high risk categorization
Risk score tool  Chi square   p
A vs C  4.339  0.0372
A vs D  1.184  0.2765
D vs C  0.8338  0.3612
A vs G  79.241   0.0001
A vs H  70.92   0.0001
D vs H  56.443   0.0001Vascular Health and Risk Management 2008:4(1) 204
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PAI-1 and factor VII activity were signiﬁ  cantly higher in the 
high risk group. The adipocytokines adiponectin and leptin 
as well as the antibody titers against C. pneumoniae were 
signiﬁ  cantly higher in the high risk in comparison with the 
intermediate risk group. HSP65 titers were also signiﬁ  cantly 
higher in the high risk group (Table 3B). Table 4B illustrates 
that all the novel lipoprotein, pro-inﬂ  ammatory, cell adhesion 
molecules, prothrombotic, adipocytokines, immune as well 
as serological plasma biomarkers were signiﬁ  cantly higher 
in the intermediate risk group when compared to the low risk 
group, except for the antibody titers to H. pylori.
Discussion
Current recommendations on the prevention of CHD stress 
the need to base intervention on an assessment of the 
individual’s total burden of risk rather than on the level of 
any particular risk factor (Pyorala et al 1994; Grundy et al 
1998; Pearson et al 2002). This follows that most people 
with CVD have several risk factors which interplay multi-
plicatively to produce their total risk burden which clinicians 
need to estimate for efﬁ  cient prevention and management. 
A number of clinical tools are available for estimation of 
absolute CVD risk and most are based upon data derived 
from the Framingham Heart Study (FHS), the participants of 
which were white Americans (Anderson et al 1991). Baseline 
absolute risk of this most intensively studied population is 
dissimilar to the risk estimated in other studies (Cappuccio 
et al 2002; Thomsen et al 2002; de Visser et al 2003; Liu 
et al 2004; Reissigova and Zvarova 2007). Available evi-
dence suggests that the absolute risk varies among different 
A. Age related risk progression-males
0
5
10
15
20
25
30
35
40
45
Age range (in years)
1
0
 
y
r
 
R
i
s
k
 
s
c
o
r
e
s
(
%
)
British (SBP) CHD
Risk
British (DBP) CHD
Risk
SCORE(TC)-Low Risk
Region
SCORE(TC)-High Risk
Region
SCORE(TC-HDL)-Low
Risk Region
SCORE(TC-HDL)-High
Risk Region
Framingham
Low Risk
Framingham
B. Age related risk progression-females
0
5
10
15
20
25
Age range (in years)
1
0
 
y
r
 
R
i
s
k
 
s
c
o
r
e
s
(
%
)
<30 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 >=70
British (SBP) CHD
Risk
British (DBP) CHD
Risk
SCORE(TC)-Low Risk
Region
SCORE(TC)-High Risk
Region
SCORE(TC-HDL)-Low
Risk Region
SCORE(TC-HDL)-High
Risk Region
Framingham
Low Risk
Framingham
1 2 34567 8 9 10
Figures 1A and 1B depict graphically the age distribution of CHD risk scores in males and females respectively.Vascular Health and Risk Management 2008:4(1) 205
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Figures 2A, 2B, 2C illustrate the gender distribution in the high, intermediate and low risk categories.
populations independent of the major risk factors (Grundy 
et al 1999; Lee et al 2001; Thomsen et al 2002; de Visser et al 
2003; Asia Paciﬁ  c Cohort Studies Collaboration 2007). To 
date, there aren’t sufﬁ  cient comparative studies which can 
quantitatively deﬁ  ne the adjustment required in the various 
risk scoring tools for application to different populations. 
Only some like the Jakarta Cardiovascular score (a modiﬁ  ed 
Framingham score developed in Indonesia) come to mind 
and neither are there too many prospective studies like the 
Framingham study in most countries that exhibit transform-
ing trends in the disease epidemiology.
To our knowledge, no other study has applied and com-
pared different CVD risk predictive systems to Asian Indians 
residing in the Indian subcontinent (studied cohort also Vascular Health and Risk Management 2008:4(1) 206
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Table 2A Comparison of traditional risk factors between high and low risk groups
Risk factor  High risk (N = 82)   Low risk (N = 1231)   p
   N  Mean ± SD  N  Mean ± SD 
TC (mg/dl)  82  195 ± 34.57   1231  173.39 ± 38.76  0.000
HDL (mg/dl)  82  36.92 ± 8.22  1231  43.36 ± 10.88  0.000
TC/HDL 82  5.52  ± 1.56  1231  4.2 ± 1.23  0.000
Age 82  60.27  ± 6.7  1223  36.41 ± 12.45  0.000
SBP 81  141.25  ± 19.27  1225  118.8 ± 12.76  0.000
DBP 81  87.85  ± 12  1225  79.48 ± 8.48  0.002
DM  52     47      0.0001
HTN  45     131      0.0001
Smoking  24     117      0.0001
Table 2B Comparison of novel pasma biomarkers between high and low risk groups
Biomarker  High risk    Low risk    Age, sex and
 N  Mean  ± SD  N  Mean ± SD  BMI adjusted
         p  value
TG (mg/dl)  82  179.23 ± 133.8  1231  122.89 ± 79.3  0.000
LDL (mg/dl)  79  125.09 ± 29.4  1216  106.13 ± 33.3  0.000
Apo A1 (g/l)  82 1.21  ± 0.25  1231  1.17 ± 0.23  0.000
Apo B100 (g/l)  82 1.12  ± 0.29  1231  0.94 ± 0.26  0.000
Lp(a) (mg/dl)  76  29.57 ± 27.8  1123  23.22 ± 26.08  0.001
CRP (ug/dl)  52 5.94  ± 7.4  500  2.89 ± 3.96  0.001
hsCRP (µg/dl)  19 3.62  ± 4.31  333  2.59 ± 3.29  0.020
IL6 (pg/ml)  42 4.36  ± 2.36  399  2.83 ± 2.5  0.068
OxLDL (mu/l)  53 64742.87  ± 20878.29  486  54282.14 ± 16483.23  0.000
sICAM (ng/ml)  28 273.35  ± 127.37  339  218.35 ± 54.64  0.104
P-selectin (ng/ml)  32 51.66  ± 18.17  356  44.18 ± 14.82  0.001
PAI-1 (ng/ml))  54 69.6  ± 62.6  664  47.54 ± 34.2  0.027
Fibrinogen (g/L)  82 4.11  ± 1.03  1226  3.62 ± 0.85  0.000
FVII.c (%)  82 112.4  ± 28.04  1226  107.02 ± 23.99  0.000
Adiponectin (ng/ml)  28 6138.45  ± 4174.46  317  5966.47 ± 3481.92  0.000
Leptin (ng/ml)  27 30.53  ± 21.84  309  23.47 ± 19.95  0.000
CMV (IU/ml)  81  14.52 ± 18.07  1227  9.55 ± 8.56  0.000
C.pneumoniae (AI)  82  0.7071 ± 0.33  1223  0.59 ± 0.37  0.026
H.pylori (Uarb/ml)  25  31.82 ± 59.7  267  22.83 ± 30.82  0.137
HSV 1 (IU/ml)  25  1.23 ± 1  274  1.01 ± 0.98  0.001
HSP 65 (mg/ml)  28  4.14 ± 7.89  338  1.71 ± 4.56  0.048
Table 2C Comparison of novel risk factors between high and low risk groups
Risk factor  High risk    Low risk    p
 N  Mean  ± SD  N  Mean ± SD
BMI 81  26.97  ± 4.66  1226  25.29 ± 4.79  0.000
WC 81  94.41  ± 10.32  1228  85.44 ± 11.85  0.000
WHR 81  0.94  ± 0.006  1228  0.89 ± 0.0078  0.000
F/h/o CVD  55    1060     0.0001
Metabolic Syndrome          
(ATPIII) 66    301     0.0001
Exercise 42    461    0.018
Diet-Veg 43    663    0.892
Diet-Non-Veg 39    562    0.825
Alcohol 14    123    0.065Vascular Health and Risk Management 2008:4(1) 207
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contains Bangladeshi subjects). In this study we subjected 
the data generated from a cohort of unaffected Asian Indians 
high at risk for development of CVD with a strong family 
history of the same, to three main predictive risk scoring 
systems. The Joint British societies’ system (1998) is based 
upon the Framingham function. All of these risk models 
were developed in a general population. Only the European 
SCORE system is derived from an assembly pool of datasets 
from 12 European cohort studies (Conroy et al 2003) and had 
a computation for high and low risk regions, which were uni-
formly applied to our study population. The TC/HDL model 
of Euro SCORE was also calculated in spite of the authors’ 
mention of there being no difference between the above and 
the TC model (Conroy et al 2003). This was done in view of 
the observed low levels of HDL-C in our cohort.
We noticed an obvious age related increase of CHD risk 
across all the utilized scoring systems and in both sexes. Most 
of the subjects (94.68%) were computed to be at low risk 
for CVD in the next ten years as mentioned in the Results 
section. These numbers of people at high risk (5.32%) appear 
to be deceivingly small for a population notoriously known 
for high prevalence of premature onset CVD. The results of 
our study are even lower than that observed by Cappuccio 
and colleagues (2002) when they applied the Framingham 
Table 3B Comparison of novel plasma biomarkers between high and intermediate risk groups
Biomarker  High risk    Intermediate risk  Age, sex and
 N  Mean  ± SD  N  Mean ± SD  BMI adjusted
         p  value
TG (mg/dl)  81  179.12 ± 134.63  227  164.52 ± 79.90 0.000
LDL (mg/dl)  78  125.664 ± 29.129  224  126.622 ± 38.392  0.033
Apo A1 (g/l)  81  1.211 ± 0.246  226  1.210 ± 0.239  0.042
Apo B 100 (g/l)  81  1.122 ± 0.292  226  1.118 ± 0.284  0.000
Lp(a) (mg/dl)  75  29.15 ± 27.75  201  23.52 ± 29.34  0.139
CRP (ug/dl)  51  5.363 ± 6.197  96  4.474 ± 5.804  0.000
hsCRP (µg/dl)  34  4.340 ± 4.370  100  4.104 ± 5.654  0.000
IL6 (pg/ml)  41  4.270 ± 2.309  77  4.231 ± 7.7457  0.020
OxLDL (mu/l)  52  64878.549 ± 21058.379  93  64200.956 ± 17056.390 0.673
sICAM (ng/ml)  28  273.349 ± 127.368  56  241.891 ± 64.331  0.334
p-selectin (ng/ml)  31  51.810 ± 18.444  64  52.090 ± 17.807  0.375
PAI-1 (ng/ml)  54  68.490 ± 62.923  138  63.096 ± 41.998  0.000
Fibrinogen (g/l)  81  4.081 ± 1.014  225  3.881 ± 0.863  0.000
FVII.c (%)  81  112.30 ± 28.20  225  117.79 ± 23.59  0.000
Adiponectin (ng/ml)  28  6138.446 ± 4174.458  52  5798.520 ± 3044.120  0.001
Leptin (ng/ml)  27  30.530 ± 21.842  52  25.3465 ± 17.494  0.000
CMV (IU/ml)  80  14.603 ± 18.162  223  12.961 ± 11.709  0.069
C.pneumoniae (Al)  81  0.7048 ± 0.3276  226  0.6714 ± 0.4017  0.034
H.pylori (Uarb/ml)  25  31.817 ± 59.700  49  26.735 ± 35.417  0.911
HSV 1 (IU/ml)  25  1.234 ± 0.998  49  1.189 ± 1.019  0.456
HSP 65 (mg/ml)  81  3.462 ± 6.083 227  2.115  ± 4.946  0.043
Table 3A Comparison of traditional risk factors between high and intermediate risk groups
Risk factors  High risk (82)    Intermediate risk (229)  p value
 N  Mean  ± SD  N  Mean ± SD
TC (mg/dl)  82  195.00 ± 34.57   229  198.51 ± 42.71  0.504
HDL (mg/dl)  82  36.91 ± 8.22  229  39.58 ± 8.51  0.015
TC/HDL 82  5.52  ± 1.56  229  5.17 ± 1.27  0.050
Age 82  60.27  ± 6.70  228  54.50 ± 8.63  0.000
SBP 81  141.25  ± 19.27  229  133.49 ± 16.25  0.001
DBP 81  87.85  ± 11.99  229  86.72 ± 8.89  0.370
DM 52    62    0.0001
HTN 45    86    0.0089
Smoking   24    42    0.0419Vascular Health and Risk Management 2008:4(1) 208
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Table 4A Comparison of traditional risk factors between intermediate and low risk groups
Risk factors  Intermediate risk (229)  Low risk (1231)    p value
 N  Mean  ± SD  N  Mean ± SD
TC (mg/dl)  229  198.51 ± 42.71  1231  173.39 ± 38.76  0.000
HDL (mg/dl)  229  39.58 ± 8.51  1231  43.36 ± 10.88  0.000
TC/HDL 229  5.17  ± 1.27  1231  4.19 ± 1.23  0.000
Age 228  54.50  ± 8.63  1223  36.41 ± 12.45  0.000
SBP 229  133.49  ± 16.25  1225  118.49 ± 12.76  0.000
DBP 229  86.72  ± 8.89  1225  79.48 ± 8.48  0.000
DM 62    47    0.0001
HTN 86    131    0.0001
Smoking   42    117    0.0002
Table 4B Comparison of novel plasma biomarkers between intermediate and low risk groups
Biomarker  Intermediate risk  Low risk    Age, sex and
 N  Mean  ± SD  N  Mean ± SD  BMI adjusted
         p  value
TG (mg/dl)  227  164.52 ± 79.90  1218  122.77 ± 79.59  0.000
LDL (mg/dl)  224  126.622 ± 38.392  1203  106.061 ± 33.274  0.000
Apo A1 (g/l)  226  1.210 ± 0.239  1218  1.171 ± 0.230  0.000
Apo B 100 (g/l)  226  1.118 ± 0.284  1218  0.941 ± 0.264  0.000
Lp(a) (mg/dl)  201  23.52 ± 29.34  1110  23.15 ± 26.09  0.001
CRP (ug/dl)  96  4.474 ± 5.804  493  2.802 ± 3.709  0.000
HsCRP (µg/dl)  100  4.104 ± 5.654  489  2.696 ± 3.248  0.000
IL6 (pg/ml)  77  4.231 ± 7.7457  393  2.810 ± 2.503  0.000
OxLDL (mu/l)  93  64200.956 ± 17056.390 478  54211.026  ± 16474.810  0.000
Sicam (ng/ml)  56  241.891 ± 64.331  336  217.867 ± 54.391  0.002
p-selectin (ng/ml)  64  52.090 ± 17.807  351  44.261 ± 14.854  0.000
PAI-1 (ng/ml)  138  63.096 ± 41.998  723  50.770 ± 47.485  0.000
Fibrinogen (g/l)  225  3.881 ± 0.863  1213  3.613 ± 0.847  0.000
FVII.c (%)  225  117.79 ± 23.59  1213  106.95 ± 23.88  0.000
Adiponectin (ng/ml)  52  5798.520 ± 3044.120  314  5970.116 ± 3492.736  0.000
Leptin (ng/ml)  52  25.3465 ± 17.494  306  23.484 ± 19.996  0.000
CMV (IU/ml)  223  12.961 ± 11.709  1214  9.538 ± 8.572  0.000
C.pneumoniae (Al)  226  0.6714 ± 0.4017  1210  0.5845 ± 0.3659  0.000
H.pylori (Uarb/ml)  49  26.735 ± 35.417  264  22.590 ± 30.363  0.179
HSV 1 (IU/ml)  49  1.189 ± 1.019  271  1.010 ± 0.983  0.001
HSP 65 (mg/ml)  227  2.115 ± 4.946  1218  1.542 ± 2.964  0.038
risk estimates to ethnic minorities in the UK. They found a 
high risk prevalence of 13.4% in Asian Indians which was 
higher than both whites and people of African origin. A study 
of ﬁ  rst generation immigrant Indian physicians in the USA 
found that the age-adjusted prevalence of MI or angina was 
3 times more in Indian men (mean age 46.4 years) compared 
with the men in the Framingham Offspring study (7.2% vs 
2.5%) (Enas et al 1996). Bhopal and colleagues (2005) also 
demonstrated by their study of South Asians in the UK that 
the European SCORE showed relatively low 10 year risk 
when compared with the Framingham model.
Although we are not aware of other studies that have exam-
ined the relevance of emerging risk factors to risk stratiﬁ  cation 
as applied to risk score models, several studies have shown 
the importance of newer risk factors in the pathophysiology 
of atherothrombosis (Ross 1999; Grundy et al 1998; Enas and 
Senthilkumar 2001; Greenland et al 2001; Albert et al 2003; 
Ridker et al 2004a, 2004b; Cushman et al 2005). Shaukat and 
colleagues (1995) analyzed the risk factor proﬁ  les of young 
siblings of UK-based Asians. When compared with their 
European counterparts, the young Asians (mean age 22 years) 
were more sedentary, centrally obese, insulin resistant, had 
higher levels of Lp(a), showed a prothrombotic tendency with 
elevated levels of PAI-1, and reduced tPA activity.
Findings from our study certainly seem to imply that 
novel risk factors can make a signiﬁ  cant contribution to Vascular Health and Risk Management 2008:4(1) 209
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CVD risk prediction in addition to the traditional risk factors 
used by the various models. In this study we observed, as 
expected, signiﬁ  cantly higher prevalence of the traditional 
risk factors in the high risk group as compared with the low 
risk group. On examination of the novel plasma biomarkers 
(Table 2B) that are not used by the risk scoring models, our 
ﬁ  ndings were very interesting, as revelation of their distribu-
tion between the high risk and low risk group (Framingham 
model) became apparent. We analyzed various phenotypes: 
lipid, pro-inﬂ  ammatory, pro-thrombotic, ﬁ  brinolytic, adipo-
cytokines, cell adhesion molecules, and serological markers, 
which serve as injurious stimuli to the endothelium and/or 
are constituents of the atherosclerotic plaques, or lead to 
the instability of a plaque. As mentioned in the results sec-
tion, we found signiﬁ  cantly higher levels of these ‘novel’ 
biomarkers in the high risk group. The order of prevalence 
of traditional risk factors and novel plasma biomarkers was 
descending from the intermediate to the low risk groups 
(Tables 3A, 3B, 4A, and 4B).
The AHA deﬁ  nes obesity as a major risk factor for CVD 
(Grundy et al 1999). We found signiﬁ  cantly higher BMI in 
the high risk group as against the low risk one. Risk is fur-
ther accentuated when obesity has a predominant abdominal 
component (Raji et al 2001; Misra et al 2005; Deepa et al 
2006). In lieu with this concept we found signiﬁ  cantly higher 
WC and WHR in the high risk cohort when compared to the 
low risk cohort. The Metabolic syndrome as ﬁ  rst deﬁ  ned by 
Reaven (1988) is a cluster of insulin resistance with hyper-
tension, dyslipidemia and obesity. MS is a signiﬁ  cant risk 
factor for development of CVD and is found to be highly 
prevalent in the Asian Indian population (Misra and Vikram 
2002; Shah et al 2005; Chow et al 2007; Deepa et al 2007; 
Ramachandran et al 2007). In our study we have designated 
MS to the participants using the NCEP–ATPIII guidelines 
(1998) and ﬁ  nd signiﬁ  cantly larger number of people with 
MS in the CVD high risk group.
Limitations
This study applies the risk functions and calculates a total 
risk burden at a single point in time and does not offer any 
information on the progression of risk in an individual 
over a period of time. While thresholds for risk factors are 
useful in clinical decision making, it is also recognized 
that risk factors operate in continuum rather than an all or 
none phenomenon (Bhal et al 2001). Ideally, prospective 
validation of the risk functions should be performed and 
until a cohort study like ours produces results, consideration 
should be given to whether an adjustment factor should 
be applied to the calculated risk scores of Asian Indians 
(Quirke et al 2003).
Conclusion
The key to combating the globally rising incidence of CVD 
lies in the identiﬁ  cation and control of known and emerg-
ing risk factors by a population based strategy aimed at 
comprehensive risk reduction. This study shows that the 
Framingham-based risk scores (Framingham and the Joint 
British Societies) and the European SCORE underestimates 
the risk of cardiovascular disease morbidity/mortality in men 
and women from an estimated high risk cohort of Asian Indi-
ans. Disproportionate underestimation of risk may contribute 
to health inequalities and more signiﬁ  cantly may mean that 
risk-reducing treatments are not being offered to those who 
need them the most. We realize however, the validity of the 
calculated risk scores can only be assessed by a follow up 
process of our cohort that is under way. Our ﬁ  ndings also 
illustrate that ‘Novel’ risk factors and plasma biomarkers not 
used in the risk scoring systems show signiﬁ  cant association 
with high CVD risk scores for Asian Indians. It is of utmost 
importance to determine the independent predictive power 
of emerging risk factors. Thus, it may be more relevant to 
develop an indigenous predictive risk scoring model for 
people of Indian origin, with inclusion of their unique risk 
proﬁ  les.
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